Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

Neupogen

filgrastim
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Nypozi INJECTION, SUBCUTANEOUS 300 mcg/0.5 mL, 480 mcg/0.8 mL    
Neupogen SOLUTION, INJECTABLE 480 mcg/1.6 mL, 300 mcg/mL    
Neupogen SOLUTION, INJECTABLE 600 mcg/mL    
Granix SOLUTION, SUBCUTANEOUS 300 mcg/0.5 mL, 480 mcg/0.8 mL    
Nivestym SOLUTION, SUBCUTANEOUS 300 mcg/0.5 mL, 480 mcg/0.8 mL    
Releuko SOLUTION, SUBCUTANEOUS 300 mcg/0.5 mL, 480 mcg/0.8 mL    
Zarxio SOLUTION, SUBCUTANEOUS 300 mcg/0.5 mL, 480 mcg/0.8 mL    
VIEW MORE Hematopoietic Agents
CLASS
201600
Comments:

New FDA Indications

G-CSF Inpatient Criteria for Use

Neupogen, Zarxio, Nivestym, Releuko, Nypozi, and Granix have all been classified as therapeutically equivalent and should be interchanged in a 1:1 ratio at the same dosing interval based on the lowest cost agent at the time.

Releuko is the preferred product for adult and pediatric inpatient and outpatient use (updated November 2024)

 

Dose rounding (Adults):

  • Patients < 75 kg: 300 mcg dose
  • Patients > 75 kg: 480 mcg dose

 

Reviewed: 26 January 2016, 25 Sept 2018 (Nivestym), May 2025 (Nypozi) Sept. 2022 (Releuko),

Updated: December 2022 (Dose Rounding)

Filgrastim-pbbk (Releuko)

Filgrastim-txid (NYPOZI) Spotlight.pdf

Last updated: Jun. 12, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved